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Abstract
Background: Bisphosphonates are a main component in the therapy of osteoporosis and other bone
resorptive diseases. Previous studies have shown a positive effect of systemically applied bisphosphonates on
fracture healing. Nevertheless high doses are related to side effects like osteonecrosis of the jaw, nephrotoxis
and gastrointestinal symptoms. In this study we investigated the effect of locally applied pamidronate on
fracture healing.
Methods: In a rodent model a simple femur fracture was set in female Wistar rats. We performed
intramedullary fixation of the fracture and placed a collagen matrix around the fracture area. One group was
treated with pamidronate, the other group with placebo via the matrix.
To investigate the volume and quality of the callus we used micro-CT (μCT) and histology after 14 and
28 days.
Results: Our results show a positive influence of local applied pamidronate on callus volume. After 14 days
an insignificant increase of callus volume in the treated animals was seen. 28 days after trauma the increase
of callus volume in the treatment group was significantly higher in comparison to the control group.
Osteonecrosis was not seen.
Conclusions: Locally applied bisphosphonates increase the callus volume in fracture healing.
Background
Osteoporosis is a major health problem of the elderly
western society and gains economical importance [1, 2]
besides its obvious impact on clinical practice. The risk
of fractures is directly related to bone density [3]. In
addition the incidence of falls and fall-related injuries
rises with age [4]. Therefore fracture fixation in osteope-
nic bone has become a major task in modern ortho-
paedic surgery. Postoperative implant loosening is often
observed, and ‘cutting out’ of implants in the femoral
head is a common complication. In the elderly a rapid
mobilisation after surgery is necessary to reduce the in-
cidence of complications like pneumonia and venous
thromboembolism as well as mental confusion.
Bisphosphonates are a main component of osteopor-
osis therapy and other diseases involving increased bone
resorption. Osteoporosis is initially treated with oral calcium,
vitamin D and Bisphosphonates [5]. Bisphosphonates reduce
the activity of osteoclasts by binding hydroxyapatite crystals
and impair the osteoclasts ability to resorb bone [6]. In the
resorption lacuna with its exposed calcium ions on bone
surface a high dose of the bisphosphonates accumulates.
The agent is then resorbed by the active osteoclast. On a
cellular level bisphosphonates inhibit steroid synthesis by
inhibiting the farnesyl diphosphate synthase (FPPS) in the
mevalonate pathway. Thereby the synthesis of essential lipid
sidechains of membrane binding proteins is impaired. In ab-
sence of lipid sidechains it is impossible for proteins to bind
to the cell membrane and they are functionless [7–9]. Sub-
sequently the activity of the osteoblasts overweighs and bone
resorption is reduced [10]. An emerging concept in modern
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trauma surgery is therefore to develop biological augmenta-
tion techniques in order to promote fracture healing.
Previous studies have shown a positive effect of bispho-
sphonates on fracture healing [11]. In most of these stud-
ies bisphosphonates were given systemically. Based on the
poor bioavailability of bisphosphonates high doses were
necessary. These can cause side effects like osteonecrosis
of the jaw, nephrotoxicity, gastrointestinal symptoms, etc.
[12]. Wermelin et al. have studied the local effect of
bisphosphonates on implant fixation [13]. The authors in-
vestigated the fixation of bisphosphonate-coated screws in
rat tibias demonstrating improved screw pull out resist-
ance when bisphosphonates were applied.
Greiner et al. [14] investigated locally applied zoledro-
nic acid via coated implants in fractured rodent tibiae.
Bending tests and review of plain radiographs revealed
improved mechanical stability of the bones of animals
treated with zoledronic acid but the results were not
supported by histological or high-resolution radiological
studies. Therefore we used μCT to image callus forma-
tion and callus volume. Histology was performed to in-
vestigate cellular processes.
Our rationale was to make use of the positive effects of
bisphosphonates in fracture healing while reducing the
side effects of systemically application by local application.
Methods
Animals
44 female Wistar-rats (mean weight 200 ± 10) were ob-
tained from the local service unit of the author’s institu-
tion. The animals were kept one per cage with free
access to water and maintenance diet. The rodents were
allowed free movement about their cages. The lighting
was maintained on a 12-hour light-dark cycle.
After surgery the animals received analgesia (100 mg/kg
Metamizol sodium (Novalgin®, Hoechst, Unterschleissheim,
Germany) with the drinking water. The animals were sacri-
ficed on day 14 or 28 after the surgical procedure.
Surgical procedure
The animals were randomized in two groups. The first
group was treated with pamidronate (Pamifos® - Medac
GmbH, Wedel) 0.6 mg/kg, the other group was treated
with placebo (NaCl 0.9 % Fresenius Kabi AG, Bad Hom-
burg). Anaesthesia was applied (Fentanyl 0.005 mg/kg,
Midazolam 2.0 mg/kg und Medetomidin 0.15 mg/kg) in-
traperitoneally. First the intramedullary fixation through
a median parapatellar insertion at the knee was per-
formed as described by Gabet et al. [15]. A cannula was
drilled into the fossa intercondylaris and advanced into
the femur. Then the wound was closed and a standard
trauma was applied to the right femur as described by
Bonnarens [16]. Afterwards through a second surgical
approach on the lateral femur, a sub vastus approach,
the collagen matrix (soaked with pamidronate or pla-
cebo) was laid around the fracture region and fixed with
a suture. The wound was closed again and anaesthesia
was antagonized by Naloxon 0.12 mg/kg, Flumazenil
0.2 mg/kg and Atipamezol 0.75 mg/kg.
Micro CT analysis
The bones were scanned in a μCT Scanner (vivaCT 40,
Scanco Medical AG, Bassersdorf, Switzerland) with 70
kVp, 114 mA and 1300 ms integration time at 10.5 μm
resolution in 1000 slices of the fracture region as de-
scribed before [17]. During scanning, the femoral bones
were placed in phosphate buffered saline. For quantita-
tive analysis of the bone formation the μCT Evaluation
Program Version 6.5-1 (Sanco Medical, Bassersdorf,
Switzerland) was used to obtain the volume of interest.
Based on histogram of attenuation distribution, tissue
was segmented into highly mineralised tissue (270 –
400) and low mineralised tissue (180 – 269) in per mille
of maximal image grey value [15].
Preparation of specimens and histologic assessment
After the μCT scan bone histology was performed to in-
vestigate the micro-architecture of the callus.
For calcified histology the bones were fixed in 10 % neu-
tral buffered formalin for 14 days at room temperature,
dehydrated with ascending concentrations of ethanol and
embedded in methylmethacrylate for 5 days at 4 °C.
Afterwards the tissue was soaked in methyl methacrylat
monomer, nonpylphenyl-polyethyleneglycol acetate and
azoisobutyronitrile (all from Sigma-Aldrich, St. Louis, USA).
The blocks were released from the glass vials and sections
of 40 μm were sawed and grinded using an EXAKT dia-
mond saw system (Exakt, Norderstedt, Germany). The sam-
ples were lubricated with 0.1 % formic acid for 2 minutes
and washed with water afterwards. The sections were sub-
merged in 20 % methanol for one hour and stained with
toluidine blue or haematoxylin and eosin.
Statistical analysis
We used a standard statistical program (GraphPad Soft-
ware Inc., La Jolla, CA USA) to perform a Kolmogorov-
Smirnov normality test. Statistical significance was eval-
uated using the Mann-Whitney test. Volumes of were
illustrated with box and whisker plots.
Results
All animals recovered quickly after surgery and mobilized
fully within one day. No signs of pain or dysfunction in
physical motion were recognized after one day. Five animals
died during anaesthesia. No animal had to be excluded be-
cause of implant dislocation or soft tissue infection. Six ro-
dents were excluded because of multifragmentary fractures.
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Histology
Callus formation and fracture healing were investigated
by standard calcified bone histology. With this method
we were able to illustrate the cellular and mineralised
components of the callus and the new bone formation.
14 days after trauma the fracture gap was still visible.
Tolouidine blue staining showed the first connective tis-
sue between the bone ends (Fig. 1).
After 28 days the fracture healing was not complete.
There was partial bony bridging of the fracture gap (Fig. 2)
and sufficient callus had arisen. No clear differences were
determined between the two groups.
Micro CT scans of the fracture zone
The callus volume was determined in the fracture region
(Fig. 3). After 14 days there was more callus in the animals
treated with Bisphosphonates (60.94 mm3 ± 11.28 mm3; n
= 12) than in the control group (52.85 mm3 ± 16.58 mm3;
n = 9). But this increase was statistically not significant (p =
0.1264) (Fig. 4a).
Fig. 1 Photomicrography of fracture callus from rat femur. Panoramic views and high magnification photomicrography of fracture healing and
callus formation was illustrated using calcified bone histology technique with toluidine blue staining. The magnification points up the
remodelling zone within the fracture gap. 14 days after fracture the fracture gap (*) and a sufficient callus (C) is noticeable. (MN) Marknail; (*)
fracture gap; (C) callus
Fig. 2 Photomicrography of fracture callus from rat femur. Panoramic views and high magnification photomicrography of fracture healing and callus
formation was illustrated using calcified bone histology technique with toluidine blue staining. The magnification points up the remodelling zone
within the fracture gap. 28 days after fracture the fracture gap (*) and callus (C) is noticeable. (MN) Marknail; (*) fracture gap; (C) callus
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At this time the difference in cortical bone volume was
similarly insignificant (BP: 42.01 mm3 ± 16.65 mm3 ; n =
12; control: 28.14 mm3 ± 10.71 mm3; n = 9; p = 0.0579).
28 days after trauma the increase of the callus volume in
the treated group (94.03 mm3 ± 17.63 mm3 ; n = 14) was
significantly higher (p = 0.0034) in comparison to the con-
trol group (63.43 mm3 ± 21.49 mm3 ; n = 9) (Fig. 4b).
28 days post trauma there was no statistical significant dif-
ference (p = 0.4004) in bone volume of treated (60.52 mm3
± 25.08 mm3; n = 14) and untreated animals (61.94 mm3 ±
20.95 mm3 ; n = 9).
Discussion
In this study we have investigated the effect of local ap-
plication of bisphosphonate via a bisphosphonate loaded
collagen matrix in a well established fracture model.
Previous studies indicate an increase of callus volume
in fracture healing under bisphosphonate application
[18–20]. In these studies the agent was given systemic-
ally. Goodship et al. report that callus volume was in-
creased under treatment with pamidronate in a sheep
model. Nyman and colleagues investigated the effect of
high doses of subcutaneously injected clodronate on
fracture healing in tibia fractures in rats. The results
show that there is a higher calcium content in the
callus when treated with clodronate [19]. Li et al. dem-
onstrate that significantly larger callus arises when
incadronate was injected before and after trauma [21].
Despite all favourable effects described in the literature
side effects of the systemic treatment with bisphospho-
nates do still represent a major obstacle. The group
around Villa investigated the bisphosphonate related
osteonecrosis of the jaw (BRONJ) in female patients
with postmenopausal osteoporosis. With continuous
bisphosphonate therapy they report 9 % osteonecrosis
of the jaw [22]. Perazella et al. described the nephrotox-
icity of intravenous bisphosphonate therapy. The tox-
icity depends on the dose and the infusion time [23].
Hyldstrup et al. demonstrated in their study the poor bio-
availability of oral applied pamidronate. The bioavailability
depends on the oral dose and showed high intraindividual
variations [24].
Fig. 3 Micro-CT Images of the fracture region. On the right side images of the treated specimens at the different timepoints. On the left images
of the control group. Red coloured is the cortical bone (highly mineralised tissue: 270 – 400 per mille of maximal image grey value).
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Locally applied bisphosphonates therefore offer the
distinct advantages of a reduced dose that theoretically
causes less side effects and while the local effective dose
is increased. So far to our knowledge there is no study
investigating the effect of locally applied bisphosphonate
on fracture healing.
Skoglund et al. investigated the effect of local applied
simvastatin in fracture healing. The group compared the
continuous locally applied HMG-CoA reductase inhibitor
to daily subcutaneous application. The locally applied sim-
vastatin showed a positive effect on biomechanical proper-
ties of the newly formed callus [25].
Our results demonstrate a positive effect on fracture
healing of locally applied bisphosphonate. After 14 days
the callus volume was increased in the treated group. The
difference became statistically significant after 28 days. In
keeping with these results previous studies showed in-
creased callus volume after systemically applied bispho-
sphonates [18, 20].
At no time point the bione volume was significantly in-
creased in either group. After 14 days the bone volume
was slightly increased in the treated rodents. After 28 days
the increase turned into a slight decrease and the control
group showed slightly higher bone volume. A possible ex-
planation for the phenomena is a delayed bone turnover
under bisphosphonate therapy as described before [26].
On a cellular level histology does not reveal osteonecrosis,
abnormal bone healing or inflammation.
The rodent fracture model we used is an established
and commonly used model to investigate fracture healing.
It is a cheap and easy to handle model in contrast to larger
animals. Nevertheless certain aspects of rodent fracture
healing may well be used to investigate basic mechanisms.
The limited amount of animals in this study is due to eth-
ical considerations. When all animals included in this
study were analysed it seemed inappropriate to further in-
crease the number tested as our results seemed convin-
cing. Statistically there is less power of the cohort.
Limitations of the study presented here comprise lack
of mechanical testing, which would be necessary to be
investigated in further studies.
Conclusions
Locally applied bisphosphonates increase the callus volume
in fracture healing. There is no increased bone volume under
the influence of bisphosphonate. Biomechanical testing will
be necessary to investigate the mechanical abilities of the
newly formed tissue. With local application lower doses of
bisphosphonates may be effective which could lead to a re-
duction of side effects.
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Fig. 4 Callus volume measured in μCT. Whiskers from minimum to
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untreated group (52.85 mm3 ± 16.58 mm3; n = 9) and on the right
pamidronat treated group (60.94 mm3 ± 11.28 mm3; n = 12). b Callus
volume 28 days after trauma. On the left untreated group
(63.43 mm3 ± 21.49 mm3 ; n = 9) and on the right pamidronate
treated group (94.03 mm3 ± 17.63 mm3 ; n = 14).
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